H. Lundbeck grants Otsuka co-development and commercialization rights to nalmefene to treat alcohol dependency in Japan

H. Lundbeck A/S

Denmark / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Otsuka Pharmaceutical Co. Ltd.

Japan / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced